Vieworks announced on the 24th that it participated in the 'USCAP Annual Meeting 2025' held in Boston, USA from the 24th to the 26th and introduced its slide scanner, 'VISQUE DPS (Digital Pathology System),' to the North American market for the first time. Through this participation, Vieworks plans to further accelerate its advance into major pathology markets such as the US and Europe, as well as major domestic hospitals where the system has recently begun supplying.
Slide scanners are key equipment used in the diagnosis of diseases such as cancer and clinical research experiments in the fields of tissue pathology, liquid cell, and immunopathology examinations. Currently, digital pathology diagnosis technology is rapidly spreading, centered around the US and Europe. Accordingly, Vieworks began developing a prototype model in 2021, obtained domestic approval in 2023, and launched 'VISQUE DPS' with upgraded functionality early this year, thereby entering full-scale commercialization. This product is included in the 'VISQUE' series, Vieworks' bio-imaging solution brand, and has further enhanced the perfection of its main business.
'VISQUE DPS' is an ultra-high-speed digital pathology diagnostic scanner that reconstructs tissue samples composed of glass slides into high-resolution WSI (Whole Slide Image), converting from analog microscopic diagnostic methods to digital methods. This allows patients' tissue slides to be stored semi-permanently in digital form, and enables collaborative treatment and remote treatment. Up to 510 slides can be loaded at once, generating 83 WSIs per hour, which is the fastest among existing slide scanners.
In addition, Vieworks applied its own 'realtime extended focus mod' technology that uses its high-resolution camera to capture three images with different focuses in a single scan and synthesizes only the sharp parts of these images. Through this technology, the focal length is extended by more than three times that of existing scanners without increasing the scan time and WSI capacity, and the WSI resolution is greatly improved. The technology has been patented in Korea.
Vieworks developed the product by reflecting the needs of professors and specialists in the department of pathology at large domestic hospitals, and improved the perfection through long-term self-verification, and in 2023, received manufacturing approval for 'cell and tissue pathology testing devices' from the Ministry of Food and Drug Safety.
A Vieworks official said, “We have successfully localized ‘VISQUE DPS’ digital pathology diagnosis equipment and its excellent functionality has been recognized. It was introduced to a large domestic hospital in December of last year, and inquiries related to it are continuing from other institutions,” adding, “We plan to accelerate our entry into the digital pathology diagnosis market in line with the global trend of personalized precision medicine and collaborative treatment.”
- See more related articles
You must be logged in to post a comment.